IN2014DN01992A - - Google Patents

Info

Publication number
IN2014DN01992A
IN2014DN01992A IN1992DEN2014A IN2014DN01992A IN 2014DN01992 A IN2014DN01992 A IN 2014DN01992A IN 1992DEN2014 A IN1992DEN2014 A IN 1992DEN2014A IN 2014DN01992 A IN2014DN01992 A IN 2014DN01992A
Authority
IN
India
Prior art keywords
methyl
aminosulfonyl
thiazol
pyridinyl
phenyl
Prior art date
Application number
Other languages
English (en)
Inventor
Wilfried Schwab
Alexander Birkmann
Kerstin Paulus
Kurt Vögtli
Dieter Haag
Stephan Maas
Kristian Ruepp
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of IN2014DN01992A publication Critical patent/IN2014DN01992A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN1992DEN2014 2011-09-26 2012-09-26 IN2014DN01992A (enrdf_load_html_response)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11007803A EP2573085A1 (en) 2011-09-26 2011-09-26 N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
PCT/EP2012/068958 WO2013045491A1 (en) 2011-09-26 2012-09-26 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations.

Publications (1)

Publication Number Publication Date
IN2014DN01992A true IN2014DN01992A (enrdf_load_html_response) 2015-05-15

Family

ID=46889071

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1992DEN2014 IN2014DN01992A (enrdf_load_html_response) 2011-09-26 2012-09-26

Country Status (11)

Country Link
US (5) US9119786B2 (enrdf_load_html_response)
EP (1) EP2573085A1 (enrdf_load_html_response)
JP (1) JP6043356B2 (enrdf_load_html_response)
KR (1) KR20140066705A (enrdf_load_html_response)
CN (1) CN103842360B (enrdf_load_html_response)
AU (1) AU2012314473B2 (enrdf_load_html_response)
IN (1) IN2014DN01992A (enrdf_load_html_response)
MX (1) MX364094B (enrdf_load_html_response)
RU (1) RU2606628C2 (enrdf_load_html_response)
WO (1) WO2013045491A1 (enrdf_load_html_response)
ZA (1) ZA201401774B (enrdf_load_html_response)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
BR112015019220A2 (pt) 2013-02-12 2017-07-18 Aicuris Gmbh & Co Kg uso de um inibidor de helicase-primase; uso de uma composição farmacêutica; e composição farmacêutica
MX2017003916A (es) * 2014-09-26 2017-06-30 Millendo Therapeutics Inc Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma.
LT3135275T (lt) * 2015-08-27 2020-09-25 Grindeks, A Joint Stock Company Farmacinė kompozicija, gebanti įtraukti įvairių kristalinių modifikacijų lenalidomidą
EP4201934A1 (en) * 2016-11-28 2023-06-28 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof
AR110250A1 (es) 2016-11-28 2019-03-13 Aicuris Anti Infective Cures Gmbh Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
CA3045063A1 (en) 2016-11-28 2018-05-31 Aicuris Anti-Infective Cures Gmbh A maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-[pyrididnyl)-phenyl]-acetamide
EA202090155A1 (ru) * 2017-06-28 2020-04-20 Айкурис Анти-Инфектив Кьюрз Гмбх Устройства для интравагинального применения, включающие противовирусные соединения
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
EP4581030A1 (en) 2022-08-29 2025-07-09 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
EP4580601A1 (en) 2022-08-29 2025-07-09 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus
CN119731171A (zh) 2022-08-29 2025-03-28 组装生物科学股份有限公司 普瑞利韦的新的结晶形式

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US6355684B1 (en) * 1990-10-11 2002-03-12 Meryl J. Squires Antimicrobial treatment for herpes simplex virus and other infectious diseases
US6348503B1 (en) 1996-02-12 2002-02-19 Meryl J. Squires Method and topical treatment composition for herpesvirus hominis
US9662360B2 (en) 2008-10-09 2017-05-30 Meritus Corporation Treatment of herpes, pseudomonas, staph, and hepatitis
DOP2000000109A (es) 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
CA2412720A1 (en) * 2000-06-15 2001-12-20 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity
DE10129716A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10129714A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE10129717A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10131128A1 (de) * 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
JP2007314516A (ja) 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd 2以上の置換基を有するベンゼン化合物を含有する医薬
MX2008015638A (es) 2006-06-09 2009-01-09 Icos Corp Acidos fenil aceticos sustituidos como antagonistas de dp-2.
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
BR112015019220A2 (pt) * 2013-02-12 2017-07-18 Aicuris Gmbh & Co Kg uso de um inibidor de helicase-primase; uso de uma composição farmacêutica; e composição farmacêutica
MX2017003916A (es) 2014-09-26 2017-06-30 Millendo Therapeutics Inc Forma de medicamento solido de clorhidrato de n-(2,6 bis (1 metiletil)fenil)-n'-((1-(4-(dimetilamino)fenil)ciclopentil) metil)urea y composiciones, metodos y kits relacionados con la misma.
EP4201934A1 (en) 2016-11-28 2023-06-28 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof
CA3045063A1 (en) 2016-11-28 2018-05-31 Aicuris Anti-Infective Cures Gmbh A maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-[pyrididnyl)-phenyl]-acetamide
KR102335327B1 (ko) 2017-04-28 2021-12-03 현대자동차 주식회사 수냉식 이지알 쿨러
EA202090155A1 (ru) 2017-06-28 2020-04-20 Айкурис Анти-Инфектив Кьюрз Гмбх Устройства для интравагинального применения, включающие противовирусные соединения

Also Published As

Publication number Publication date
US10137117B2 (en) 2018-11-27
MX364094B (es) 2019-04-12
US9592225B2 (en) 2017-03-14
RU2606628C2 (ru) 2017-01-10
EP2573085A1 (en) 2013-03-27
US9889124B2 (en) 2018-02-13
JP2014527995A (ja) 2014-10-23
US9119786B2 (en) 2015-09-01
USRE49697E1 (en) 2023-10-17
US20150366849A1 (en) 2015-12-24
CN103842360B (zh) 2016-06-22
CN103842360A (zh) 2014-06-04
ZA201401774B (en) 2015-12-23
US20140065224A1 (en) 2014-03-06
US20160008341A1 (en) 2016-01-14
MX2014003623A (es) 2014-05-30
US20170348297A1 (en) 2017-12-07
KR20140066705A (ko) 2014-06-02
JP6043356B2 (ja) 2016-12-14
RU2014116621A (ru) 2015-11-10
AU2012314473B2 (en) 2015-09-17
WO2013045491A1 (en) 2013-04-04
AU2012314473A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
IN2014DN01992A (enrdf_load_html_response)
IN2014DN01993A (enrdf_load_html_response)
MX343837B (es) Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.
MY172924A (en) Neprilysin inhibitors
MD4490B1 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
IN2014CN04530A (enrdf_load_html_response)
SI2318004T1 (sl) Farmacevtski sestavki, ki vsebujejo kristalinično obliko Y posakonazola
PL2785711T3 (pl) Pochodne 2-(fenylo lub piryd-3-ylo)aminopirymidyny jako modulatory kinazy lrrk2 do leczenia choroby parkinsona
SG195106A1 (en) Trpv4 antagonists
IL220707A (en) Annotations 2– (phenyl / heteroaryl) - [3,1] oxazolo [4,5– d] pyrimidine, process for preparation and pharmaceutical preparations containing them
MY176244A (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
PH12015502632A1 (en) Cxcr7 receptor modulators
EP2514720A4 (en) PREPARATION FOR HIGH DENSITY ZNO NANOPOUNTS
PL2770844T3 (pl) Pochodząca z pomidorów kompozycja zawierająca zwiększone poziomy 5’-monofosforanu inozyny
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
IN2014DN06122A (enrdf_load_html_response)
MA33883B1 (fr) Procédé de synthèse et forme cristalline du chlorhydrate de 4-{3-[cishexanhydrocyclopenta[c] pyrrol-2(1h)-yl]propoxy}benzamide ainsi que les compositions pharmaceutiques qui la contiennent
SI2612850T1 (sl) Delta kristalinična oblika argininske soli perindoprila, postopek za njeno pripravo in farmacevtski sestavki, ki jo vsebujejo
MX2013012773A (es) Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas.
IL228462B (en) The film-forming composition for sustained release depends on the ph of an active ingredient
IN2015DN03869A (enrdf_load_html_response)
MX346497B (es) Compuestos para la diferenciacion de celulas madre mejorada en hepatocitos.
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
WO2012023145A3 (en) Prasugrel hydrochloride crystalline particles